FLT3 tyrosine kinase inhibitors have been developed for several years, and the type I FLT3 inhibitor (i.e., that has activity against FLT3-ITD and TKD mutations) midostaurin was approved in 2017 for the treatment of newly diagnosed FLT3-mutated AML, in combination with intensive chemotherapy [7]. Here, FLT3 is linked to acute myeloid leukemia.